Home Blog Page 1903

WIP Capital Investments Pty Ltd (ACN 686 632 066) Issues Offer Letter to Prospective Note Subscribers

WIP Capital Investments Pty Ltd (ACN 686 632 066) as trustee for WIP Capital Investments Trust (the Issuer)

MELBOURNE, Australia, Oct. 13, 2025 /PRNewswire/ — The Issuer would like to offer institutions the opportunity to participate as a noteholder under a loan note deed poll, dated as of 27 May 2025, as amended from time to time (the Loan Note Deed) in respect of notes to be issued by the Issuer under the Loan Note Deed, as described in more detail in the commercial terms sheet attached to this offer letter (the Notes). The proceeds of the Notes will be used by the Issuer to, among other things, make investments that are consistent with the Investment Plan set out in the trust deed of the WIP Capital Investments Trust (the Trust).

For the purpose of carrying out certain regulated activities, the Issuer is appointed by Wingate Financial Services Pty Ltd (ACN 106 480 602) (the Investment Manager or Licensee) as its corporate authorised representative. This offer letter, and any offer in respect of the Trust, will be made by the Licensee under an intermediary authorisation agreement between the Issuer and Licensee, where the Licensee will make offers to arrange for the issue, variation and disposal of financial products in connection with the Trust. The Issuer will then issue the financial products in accordance with the offer, if it is accepted.

Tax Act Public Offer

The Notes will be documented under the Loan Note Deed in accordance with section 128F of the Income Tax Assessment Act 1936 (Cth) of Australia (the Tax Act). This letter constitutes an offer to issue the Notes in accordance with the “public offer test” in subsection 128F(3) of the Tax Act.

It is intended that the Notes will be issued in a manner that satisfies the public offer test and other requirements of section 128F of the Tax Act. Accordingly, Offshore Associates (as defined below) of the Issuer will not be permitted to acquire an interest in the Notes.

Participants will be required to make customary representations, warranties and covenants regarding their status to ensure compliance with Australia’s interest withholding tax exemption regime, and in particular, will be asked to confirm that except as disclosed to the Issuer at the time of this offer, they are not so far as they have actual knowledge, an Offshore Associate of the Issuer.

In this letter, “Associate” has the meaning given in subsection 128F(9) of the Tax Act and “Offshore Associate” means an Associate who would acquire an interest in the circumstances specified in subsections 128F(5)(b) and (c) of the Tax Act.

General Conditions of Participation

Final allocations will be determined by the Issuer in its absolute discretion. The Issuer reserves the right to scale back or accept oversubscriptions, and to withdraw this offer at any time or close or extend the review period for considering this offer at any time before or after the stated date for receipt of responses.

Each offered investor must independently make its own credit analysis and decision to enter into the transaction.

Principal Terms

The details of the Loan Note Deed are set out in the term sheet in Schedule 1 to this letter (the Term Sheet).

Structure Diagram

The structure diagram included in Schedule 2 to this letter (the Structure Diagram) is provided for illustrative purposes to assist prospective investors in understanding, in summary form, certain aspects of the proposed structure relating to the offer of the Notes. It does not purport to depict all legal, tax, accounting or operational considerations relevant to the offer or the structure. The Structure Diagram may be subject to change and such changes may not be reflected in the Structure Diagram. No representation or warranty is made by the Issuer as to completeness or accuracy of the Structure Diagram.

Confidential Information

Please note that the recipients of this offer are required to keep all information regarding the Notes, the Loan Note Deed, and the Trust (the Confidential Information), confidential. Recipients are not to discuss the Confidential Information with each other or disclose any details to any third parties without the prior written consent of the Issuer. This letter must not be reproduced, used or given to any other person, in whole or in part, for any purpose other than that for which it is intended.

For the avoidance of doubt, the Issuer may disclose any Confidential Information and the information contained in this letter as required by law or regulation or by any applicable stock exchange without the need to obtain any prior approval or consent.

Singaporean Selling Legend

The offer, issue, and sale of the Notes are and will be exempt from the registration and prospectus delivery requirements of the Securities and Futures Act of Singapore 2001 (SFA), and have not and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply, and you should consider carefully whether the investment is suitable for you. The Monetary Authority of Singapore assumes no responsibility for the contents of this document or any other document or material related to the offer, issue, and sale of the Notes. This offer and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Notes may not be circulated or distributed, nor may the Notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to any person in Singapore other than pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. The offer of the Notes relates to schemes which are not authorised or recognised by the Monetary Authority of Singapore and are not allowed to be offered to the retail public.

Process

If you are interested in participating as a noteholder under the Loan Note Deed you are requested to sign and return the below expression of interest by no later than 13 April 2026 to:

Wingate Financial Services Pty Ltd
Level 48, 101 Collins Street, Melbourne, Victoria 3000
Attention: Michael Sack
Email: msack@wingate.com.au 

By countersigning this letter, you are merely expressing your interest to participate as a noteholder under the Loan Note Deed. Such expression of interest is non-binding and is not intended to indicate your approval of the Term Sheet.

By countersigning this letter, you represent and warrant that your institution is not, so far as you have actual knowledge or grounds to suspect, an Offshore Associate of the Issuer.

Countersigned by

Signed:_____________________________

Name:   _____________________________

Title:     _____________________________        

Schedule 1 – Term Sheet

WIP CAPITAL INVESTMENTS TRUST

Terms

Issuer

WIP Capital Investments Pty Ltd (ACN 686 632 066) acts as trustee for the Trust.

Trust

An Australian unit trust established to make direct or indirect debt investments
across multiple asset classes and sectors in Australia known as “WIP Capital
Investments Trust”. The Trust will be predominantly funded by the issuance of
Notes to the noteholders (the Noteholders).

Domicile

Australia.

Investment
Manager

Wingate Financial Services Pty Ltd (ACN 106 480 602).

The offer

An offer to subscribe for loan notes on the terms described in the Loan Note Deed.
The offer is intended to satisfy the requirements of section 128F of the Income Tax
Assessment Act 1936
.

Issue Maximum

AU$100 million excluding co-investments, or as determined by the Issuer from
time to time in order to meet the Trust’s funding requirements.

Currency

Australian Dollars (AUD).

Security

Unsecured. 

Interest payment

Interest is linked to the underlying loans and it is targeting a return equal to the
aggregate of the RBA Cash Rate plus a variable return of 2.5% – 5.5%. The
anticipated return is not guaranteed. The interest will only be paid to the extent
there are cash receipts available for distribution.

Purpose

The Issuer will establish the Trust to gain exposure to borrowers situated in
Australia by making direct or indirect debt investments across multiple asset classes
and sectors in Australia.

Term

5 years from closing plus extension for up to 1 additional year, provided that if the
Noteholder does not request repayment of the Notes 90 days before the termination
of last day of the Term, the Notes will automatically rollover to new notes for
another 5 years on the same terms of issue as the Notes unless the Issuer determines
otherwise.

Currency Hedging

None. The Trust will make loan investments in AUD.

Fees

Nil.

Early Prepayment

The Noteholder may request early prepayment of any or all of its Notes on a
monthly basis (Early Prepayment Request). If there is sufficient cash to prepay
the Notes specified in the Early Prepayment Request, the Issuer shall prepay such
Notes in full. If there is insufficient cash available, the Issuer may prepay the Notes
the subject of Early Prepayment Request as and when the underlying loans or
investments are repaid, redeemed or otherwise disposed of.

Limitation of
liability

The Issuer enters into the transaction documents (including Loan Note Deed) only
in its capacity as trustee of the Trust. Any liability is limited to, and can be enforced
against the Issuer only to the extent to which it can be satisfied out of the assets of
the Trust out of which the Issuer is actually indemnified for the liability.

Transferability

The Noteholder can only transfer any or all of its Notes if the Issuer, in its sole
discretion, consents to the transfer in writing and satisfies other requirements set
out in the Loan Note Deed.

Governing Law

Victoria, Australia.

Caption

 

Schedule 2 – Structure Diagram

Structure Diagram
Structure Diagram

 

As an academy even older than University of Cambridge, the great wisdom, “seeking truth from facts”, took root here

CHANGSHA, China, Oct. 13, 2025 /PRNewswire/ — This is a report from Hunan Today: At the foot of Yuelu Mountain, Yuelu Academy’s red gate stands with the old couplet “Only Chu Has Talents, and Here They Shine Most.” Two young women in Hanfu—Ying and Shi—met American scholar Professor Xia (who’s studied Hunan culture for 7 years) here. Xia explained the couplet’s meaning and shared the academy’s history: it’s 300 years older than Oxford, and great minds like Zhu Xi and Mao Zedong once sought truth here. Ying asked Xia to guide them, and he agreed, changing into a scholar’s robe.

 

As an academy even older than University of Cambridge, the great wisdom, “seeking truth from facts”, took root here.

They walked the central path past three gates. Xia told Shi each gate had a role: greeting guests, reminding rules, calming minds. He explained the second gate’s inscription (from Records of the Grand Historian) meant the academy used nature to help students focus. In the lecture hall, Xia said two chairs honored the 1167 “Zhu-Zhang Debate,” where scholars argued but found common ground. He also talked about the “Seek Truth from Facts” plaque—written in 1917, it shaped young Mao (who lived here 1917-1919). In the courtyard, Xia shared Hunan’s “Unity of Knowledge and Action” spirit: “Act, don’t just know.”

As the sun set, they said goodbye. Ying thanked Xia, noting she now saw culture in the academy’s stories. Shi said, “Culture has no borders—we’ll pass this on.” Watching them leave, Xia whispered, “This legacy is with the young!” Wind rustled trees, cheering the cultural handover.

 

Smartee Launches World’s First Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

SHANGHAI, Oct. 13, 2025 /PRNewswire/ — Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improving sleep quality.

Smartee Sleep Aligners
Smartee Sleep Aligners

Addressing a global health challenge

OSAHS is one of the most prevalent sleep-related breathing disorders. Early signs often include habitual snoring caused by airway narrowing. As the condition progresses, patients may experience repeated breathing interruptions during sleep, which not only impair rest quality but are also linked to serious cardiovascular and metabolic risks.

The Smartee Sleep Aligners Series addresses this challenge through digitally customized clear aligners with a dual-splint locking system that advances the mandible while distributing occlusal forces to stabilize the jaw. This mandibular repositioning increases the volume of the velopharyngeal and oropharyngeal airways, improving airflow and alleviating OSAHS symptoms. Additionally, the appliance helps to reposition the mandible, which also leads to improved tongue base positioning, contributing to an expanded pharyngeal airway and reduced obstruction.

This device is made from a 1 mm-thick dental sheet, which offers enhanced comfort with minimal foreign body sensation. It demonstrates better patient acceptability and wear compliance.

There are two treatment options for OSAHS.

1. Smartee SA

  • Indications: Simple snoring (without apnea), mild-to-moderate OSAHS, patients intolerant to CPAP, or those unsuitable for surgery.
  • Function: Enlarge the velopharyngeal and oropharyngeal airway volume via mandibular advancement.
  • Benefit: Titration assists clinicians in efficiently identifying the optimal mandibular advancement setting.

2. Smartee SA Plus

  • Indications: Mild-to-moderate OSAHS combined with mild anterior misalignment.
  • Function:
    Daytime: Correcting anterior teeth with regular clear aligners.
    Nighttime: Maintains airway patency and reduces snoring by wearing specially designed aligners with the mandibular advancement feature.
  • Benefit: Offers both integrated daytime orthodontic correction and nocturnal snore suppression.

Global Availability

Both appliances are now available for clinicians to order directly through the Smartee Case Management System. By combining digital orthodontics with airway management, the Smartee SA and SA Plus series underscores Smartee’s commitment to delivering innovative, clinically proven, and patient-centric solutions for doctors and patients worldwide.

For more information about the Smartee Sleep Aligners, please visit: Smartee LinkedIn Newsletter

 

Agoda Data Shows 67% Rise in International Travel Interest to India During Diwali 2025

SINGAPORE, Oct. 13, 2025 /PRNewswire/ — Digital travel platform Agoda’s latest travel insights revealed a steady rise in interest for India as a destination during the upcoming Diwali week, with searches growing 24% among international travelers and domestic travelers combined.

Domestic travel interest continues to play a central role during this holiday period, with searches within India increasing by 18%. Notably, international travel interest is expanding at an even faster pace, with inbound searches by overseas travelers growing by 67% year-on-year during the holiday period.

Among the top ten international markets expressing travel interest to India during this period, South Korea stood out with searches rising more than 45 times compared to last year. Travel interest from Southeast Asia was also strong, with searches from Thailand growing nearly twofold, and interest from Malaysia rising 25%. Beyond the APAC region, travel interest from the United Arab Emirates recorded an 87% increase, while searches from the United States rose by 28%, underlining the diverse spread of interest across both regional and long-haul markets.

Beyond its vibrant displays of lamps and fireworks, for many travelers, Diwali is an opportunity to engage with India’s rich heritage, taste festive cuisine, and participate in family-centered festivities that create a sense of warmth and togetherness. The festival’s combination of visual spectacle, cultural immersion, and shared celebration makes it a compelling reason for both domestic and international travelers to visit India each year.

During Diwali, travelers are seeking destinations that blend cultural heritage with festive vibrancy. Goa topped the rank as the most searched destination for the festive period. Among the top five destinations, Udaipur and Jaipur recorded a 49% and 46% rise in searches, respectively, reflecting their reputation as centers of cultural richness. Meanwhile, searches for New Delhi doubled and Mumbai searches rose by 18%, reaffirming their positions as key metropolitan hubs for both domestic and international visitors looking to experience Diwali celebrations.

Commenting on these trends, Gaurav Malik, Country Director for the Indian Subcontinent and Indian Ocean Islands at Agoda said, “It’s wonderful to see so many international visitors eager to experience the unique cultural festivals that India has to offer. Diwali, with its traditions of light, community, and celebration, provides an unmatched opportunity for travelers to immerse themselves in India’s rich cultural fabric. What’s particularly exciting is the emergence of newer source markets such as South Korea, alongside consistent demand from regions like the Middle East and Southeast Asia. These insights reflect how cultural travel resonates across borders, and how India is increasingly being recognized as a vibrant, welcoming destination for diverse global audiences.

Agoda offers travelers a wide range of accommodations, flights, and packages at competitive prices. With exclusive deals and flexible booking options, Agoda makes it easier for travelers to plan and enjoy their festive journeys, ensuring that every trip, no matter where, becomes possible.

CommScope and Nokia Announce Combined FTTH Solution

CommScope FLX ODN integration with Nokia Broadband Easy accelerates and automates FTTH network rollouts for rapid deployment 

CLAREMONT, N.C., Oct. 13, 2025 /PRNewswire/ — CommScope (NASDAQ: COMM), a global leader in network connectivity, and Nokia today announced a joint initiative to streamline FTTH deployments in APAC by integrating CommScope FLX™ ODN  non-hardened connectorized terminals with the Nokia Broadband Easy digital automation platform for fiber rollout. The combined, turn-key solution gives service providers a digitized and assured path to FTTH with unprecedented accuracy, speed, and automation.

“One of the most persistent challenges in FTTH field deployments is achieving precise installation and provisioning of network components,” said Andrew Bond-Webster, Vice President, Broadband APAC, CommScope. “By integrating Nokia Broadband Easy with the CommScope FLX ODN solution, we’re empowering service providers to get it right the first time—every time. This minimizes rework, enables the use of less specialized technicians, and enhances rollout accuracy. The CommScope FLX ODN platform is instrumental in lowering total cost of ownership, accelerating time to market, and reducing unnecessary truck rolls—delivering greater operational efficiency and cost savings.”

“With Broadband Easy, we’re transforming fiber deployment—making it simpler, faster, and more cost-efficient for operators,” said Vimal Kothandaraman, Vice President, APAC Fixed Networks business center, Nokia. “By harnessing the power of AI alongside our deep expertise in fiber network design, and integrating the CommScope FLX ODN solution, we’re not only helping operators to save costs and reduce rollout times but also enabling them to accelerate delivery of high-speed connectivity to the next billion homes.”

The CommScope FLX™ ODN  plug-and-play fiber access terminals use advanced indexing and connectorized technology to eliminate field splicing while remaining modular and scalable. The solution is integrated with the Nokia Broadband Easy digital automation platform, allowing customers to centrally manage the entire fiber deployment process with AI-driven automation and quality assurance – from design to operations. The result is higher-quality fiber networks that are faster to deploy, more cost efficient, and ready for the future.

The joint solution is available today for CommScope and Nokia customers in APAC. It will be showcased at Network-X in Paris, France 14-16, October, 2025 and at Telecoms World Asia event in Bangkok, Thailand 18-19 November, 2025.

—END—

CommScope and the CommScope logo are registered trademarks of CommScope and/or its affiliates in the U.S. and other countries. For additional trademark information see https://www.commscope.com/trademarks. All other product names, trademarks and registered trademarks are property of their respective owners.

Media inquiries
Nokia Communications, Corporate
Email: Press.Services@nokia.com

News Media Contact:
Tan Weiwei
weiwei.tan@commscope.com 

This press release includes forward-looking statements that are based on information currently available to management, management’s beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, which could cause the actual results to differ materially from those currently expected. In providing forward-looking statements, the company does not intend, and is not undertaking any obligation or duty, to update these statements as a result of new information, future events or otherwise.

 

Ramco Payce Now Certified with Workday Global Payroll Connect

Certified Integration delivers seamless, accurate, and scalable multi-country payroll for global enterprises.

CHENNAI, India and PRINCETON, N.J., Oct. 13, 2025 /PRNewswire/ — Ramco Systems Limited announced today that Ramco Payce has been officially certified as a Workday Global Payroll Connect (GPC) partner.

Global payroll just got smarter!Ramco Payce is certified with Workday Global Payroll Connect (GPC) which means faster rollouts, consistent governance, a unified access model through Workday, and lower integration and change management costs for enterprises worldwide.
Global payroll just got smarter!Ramco Payce is certified with Workday Global Payroll Connect (GPC) which means faster rollouts, consistent governance, a unified access model through Workday, and lower integration and change management costs for enterprises worldwide.

The certification validates Ramco’s ability to deliver prebuilt, pretested integrations with Workday Human Capital Management (HCM), helping organizations standardize multi-country payroll, strengthen governance, and improve operational confidence across markets.

What Workday GPC means for Enterprises:

With Workday GPC, enterprises can maintain a consistent, Workday-first experience across countries. By leveraging Workday GPC, Ramco Payce delivers automated integrations that scale from single-country rollouts to large, multi-country programs. This enables customers to:

  • Enter country-specific payroll inputs directly in Workday
  • Track payroll progress and readiness across multiple countries in one view
  • Access final results and official documents natively within Workday once payroll is approved

For global enterprises, this means faster implementations, consistent governance, a unified access model through Workday, and lower overall cost of integration and change management.

Rohit Mathur, Executive VP & SBU Head – Global Payroll & HR, Ramco Systems, said, “Our Workday Certified Integration underscores Ramco’s commitment to simplifying global payroll at scale. By combining the Workday platform with Ramco Payce’s next-gen payroll engine, enterprises gain a unified, seamless payroll experience. It also aligns perfectly with our product vision—low-code configurability, faster implementations, and elevated employee experience.”

Trusted by 500+ customers worldwide, and powered by continuous tech innovations, Ramco Payce has been at the forefront of delivering global payroll transformation. With a global payroll coverage across 150+ countries, the solution offers seamless integration with leading HCM providers offering an end-to-end digital payroll solution that can be deployed on-cloud or leveraged as a managed service. With new features around self-service reporting, actionable payroll workspace, serverless payroll, and a quick implementation toolkit, Ramco Payce aims to deliver faster and smoother implementations. By leveraging robotic process automation, artificial intelligence, and machine learning, Ramco continues to offer a touchless payroll experience.

About Ramco Systems: 

Ramco Systems is a world-class enterprise software product/ platform provider disrupting the market with its multi-tenant cloud and mobile-based enterprise software, successfully driving innovation for over 25 years. Over the years, Ramco has maintained a consistent track record of serving 800+ customers globally with two million+ users and delivering tangible business value in Global Payroll, Aviation, Aerospace & Defense, and ERP. Ramco’s key differentiator is its innovative product development approach through its revolutionary enterprise application assembly and delivery platform. On the innovation front, Ramco is leveraging cutting-edge technologies around Artificial Intelligence, Machine Learning, RPA, and Blockchain, amongst others, to help organizations embrace digital transformation. 

For more information, please visit https://www.ramco.com/products/payce 

Follow Ramco on Twitter @RamcoSystems / @RamcoPayroll and stay tuned to https://www.ramco.com/blog

 

 

Trip.com Group and Live Nation Asia Announce Strategic Partnership to Power Concert Travel

SINGAPORE, Oct. 13, 2025 /PRNewswire/ — Concert travel is reshaping tourism in Asia, with fans crossing borders and booking trips to see the artists they love. Trip.com Group, a global leader in travel services, and Live Nation Asia, the world’s leading live entertainment company, have announced a multi-year strategic partnership to integrate travel and live music experiences across key Asian markets.


Launching across Hong Kong/Macau, Singapore, Thailand, South Korea and Mainland China, the collaboration will allow fans to seamlessly plan concert-focused trips — combining exclusive presale access to shows with flights, hotels, and curated local experiences through Trip.com Group’s platform.

This partnership marks Trip.com Group’s first step into the live entertainment travel space, reinforcing its commitment to meeting evolving traveller demands and reflecting how tourism, hospitality, and live entertainment are coming together in new ways.

The Rising Power of Music-Driven Tourism

As live music becomes a growing driver of travel, this partnership is designed to empower fans to follow the artists they love while supporting regional tourism and elevating destination appeal in Asia.

According to Trip.com’s Momentum consumer survey, which highlights the next big trends in travel, nearly 66% of Asia Pacific travellers are willing to travel internationally for concerts, with Gen Z and Millennials leading the trend. In Singapore, hotel bookings tripled during Lady Gaga’s Asia-exclusive show, while in Hong Kong, over half of concertgoers extended their stay for leisure, driving revenue across tourism sectors. Artists are also adding shows in cities like Singapore, Bangkok, and Seoul, establishing these cities as must-visit music hubs.

“Today’s music lovers are embracing immersive experiences that extend far beyond the concert itself,” said Mr Bo Sun, Chief Marketing Officer, Trip.com Group. “Through partnerships like this, we are enhancing the travel journey, adding value for fans and unlocking new cultural and economic value for destinations and the wider industry in Asia. Together, we’re proud to pioneer the future of tourism through entertainment.”

“Concert travel is redefining tourism across Asia,” said Mr James Dick, EVP of Partnerships and Media, Live Nation Asia. “Together with Trip.com, we’re helping fans turn concerts into unforgettable trips that shape the culture of entire cities.”


The partnership also creates room for collaboration with local hotels, attractions, and tourism stakeholders in these markets, building concert-driven products and experiences that encourage more bookings, longer stays, and greater destination appeal in Asia.

Turning Every Show into a Trip Worth Taking

The first launch under this partnership featured exclusive bundled experiences for K-pop powerhouse TWICE’s tour in Hong Kong. As the Official Travel Partner of the TWICE WORLD TOUR IN HONG KONG, Trip.com is giving fans exclusive presale access, bundled hotel packages, and transport options.

Similar bundles and early access will roll out across five markets in Asia, featuring global and regional superstars, and turning every show into an opportunity to explore a new destination. For example, bundles may include concert tickets paired with tickets to attractions like Hong Kong Disneyland, Rainforest Wild ASIA, sightseeing buses, and hotel rooms, elevating the entire trip.

Building on its role as BLACKPINK’s Official Sponsor in Bangkok and Hong Kong, Trip.com now also offers presale access for the upcoming BLACKPINK WORLD TOUR IN SINGAPORE and HONG KONG.

Visit Trip.com to discover more concert travel bundles, with additional packages and tour announcements coming soon.    

About Trip.com Group

Trip.com Group is a leading global travel service provider comprising of Trip.com , Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission “to pursue the perfect trip for a better world”. Find out more about Trip.com Group here: group.trip.com .

About Live Nation Entertainment

Live Nation Entertainment (NYSE: LYV) is the world’s leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, and Live Nation Sponsorship. For additional information, visit

www.livenationentertainment.com.

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

  • EVM14 becomes Everest Medicines’ internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).
  • EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines’ proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas.
  • In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor recurrence, offering hope for long-term cancer-free survival.
  • Tumor-associated antigen vaccines offer distinct advantages, including elimination of HLA screening requirements, off-the-shelf availability, lower production costs versus personalized neoantigen vaccines, and applicability across multiple tumor types.

SHANGHAI, Oct. 13, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China. This achievement marks a key milestone in the Company’s efforts to develop innovative mRNA therapeutics in oncology. EVM14 becomes Everest Medicines’ internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).

EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines’ proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas, including squamous non-small cell lung cancer (sq-NSCLC) and head and neck squamous cell carcinoma (HNSCC). EVM14 previously received IND clearance from the U.S. Food and Drug Administration (FDA) in March 2025.

“The cancer burden in China remains substantial. Neither immunotherapy nor targeted therapy can offer long term benefits to cancer patients. As a tumor-associated antigen cancer vaccine, EVM14 is designed to treat various squamous cell carcinomas,” Professor Lu Shun, the Lead Principal Investigator in China and Director of the Oncology Department at Shanghai Chest Hospital, stated: ” EVM14’s unique mechanism offers the potential to complement current treatments by enhancing the efficacy via combination therapies and helping delay disease recurrence, aligning with current trends in oncology drug development. In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor recurrence,offering hope for long-term cancer-free survival. We look forward to EVM14 demonstrating promising therapeutic potential in clinical trials, bringing new hope to more patients.”

“EVM14 is Everest’s first therapeutic mRNA cancer vaccine to achieve IND approvals in both China and the U.S. The approvals reinforces our leadership in developing therapeutic cancer vaccine as a novel immuno-oncology modality.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Tumor-associated antigen vaccines offer distinct advantages, including elimination of HLA screening requirements, off-the-shelf availability, lower production costs versus personalized neoantigen vaccines, and applicability across multiple tumor types.

The NMPA approval marks another important milestone that will accelerate clinical development in both countries. Ongoing global multicenter trials will generate valuable clinical evidence to support indication expansion and bring more treatment options to cancer patients worldwide.”

The primary endpoints of the EVM14 Phase I trial are safety and tolerability, with secondary endpoints assessing preliminary efficacy. In the targeted cancer types, 96% of patients with sq-NSCLC and 97% of patients with HNSCC expressed at least one of the five target genes.[1]. This broad expression profile, coupled with the limited efficacy of existing standard-of-care therapies, highlights a substantial unmet medical need within these patient populations.

In preclinical studies, EVM14 induced a dose-dependent antigen-specific immune response in mice and significantly inhibited tumor growth in multiple syngeneic tumor models. Notably, EVM14 demonstrated the ability to induce immune memory and prevent tumor recurrence, offering hope for long-term cancer-free survival. Furthermore, preclinical data demonstrated that the combination of EVM14 with immune checkpoint inhibitors (ICIs), such as anti-PD-1 or anti-CTLA-4 antibodies, greatly enhanced the anti-tumor activity, reduced recurrence and metastasis, and supports clinical exploration of combination therapies.

Everest Medicines’ Jiashan manufacturing site released the first GMP clinical trial batch in June 2025. This batch will support the clinical trials of EVM14 in both China and the United States. The clinical centers involved include NEXT Oncology Virginia, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center in the U.S., and Shanghai Chest Hospital in China.

About EVM14

EVM14 Injection is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) cancer vaccine. It is formulated with mRNA solution encoding 5 tumor-associated antigens (TAAs), encapsulated in a lipid nanoparticle system. After intramuscular injection, EVM14 is taken up by antigen-presenting cells (APCs) and translated into target antigens. These antigens are processed, presented to T cells by major histocompatibility complex (MHC) molecules and activated antigen-specific T cells. The activated T cells can migrate to tumor tissues, recognize, and kill the tumor cells expressing the target antigens.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

References:

  1. The Cancer Genome Atlas (TCGA) data